Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2004 Dec;1(3):e64.
doi: 10.1371/journal.pmed.0010064. Epub 2004 Dec 28.

Randomized, controlled trial of therapy interruption in chronic HIV-1 infection

Emmanouil Papasavvas  1 , Jay R Kostman, Karam Mounzer, Robert M Grant, Robert Gross, Cele Gallo, Livio Azzoni, Andrea Foulkes, Brian Thiel, Maxwell Pistilli, Agnieszka Mackiewicz, Jane Shull, Luis J Montaner
Affiliations
Randomized Controlled Trial

Randomized, controlled trial of therapy interruption in chronic HIV-1 infection

Emmanouil Papasavvas et al. PLoS Med. 2004 Dec.

Abstract

Background: Approaches to limiting exposure to antiretroviral therapy (ART) drugs are an active area of HIV therapy research. Here we present longitudinal follow-up of a randomized, open-label, single-center study of the immune, viral, and safety outcomes of structured therapy interruptions (TIs) in patients with chronically suppressed HIV-1 infection as compared to equal follow-up of patients on continuous therapy and including a final therapy interruption in both arms.

Methods and findings: Forty-two chronically HIV-infected patients on suppressive ART with CD4 counts higher than 400 were randomized 1:1 to either (1) three successive fixed TIs of 2, 4, and 6 wk, with intervening resumption of therapy with resuppression for 4 wk before subsequent interruption, or (2) 40 wk of continuous therapy, with a final open-ended TI in both treatment groups. Main outcome was analysis of the time to viral rebound (>5,000 copies/ml) during the open-ended TI. Secondary outcomes included study-defined safety criteria, viral resistance, therapy failure, and retention of immune reconstitution. There was no difference between the groups in time to viral rebound during the open-ended TI (continuous therapy/single TI, median [interquartile range] = 4 [1-8] wk, n = 21; repeated TI, median [interquartile range] = 5 [4-8] wk, n = 21; p = 0.36). No differences in study-related adverse events, viral set point at 12 or 20 wk of open-ended interruption, viral resistance or therapy failure, retention of CD4 T cell numbers on ART, or retention of lymphoproliferative recall antigen responses were noted between groups. Importantly, resistance detected shortly after initial viremia following the open-ended TI did not result in a lack of resuppression to less than 50 copies/ml after reinitiation of the same drug regimen.

Conclusion: Cycles of 2- to 6-wk time-fixed TIs in patients with suppressed HIV infection failed to confer a clinically significant benefit with regard to viral suppression off ART. Also, secondary analysis showed no difference between the two strategies in terms of safety, retention of immune reconstitution, and clinical therapy failure. Based on these findings, we suggest that further clinical research on the long-term consequences of TI strategies to decrease drug exposure is warranted.

PubMed Disclaimer

Conflict of interest statement

Competing Interests:

RMG is a paid consultant for the Bayer Guidelines Project, which develops algorithms for interpretation of drug resistance genotyping assays; received honoraria and research support from ViroLogic and Visible Genetics; received honoraria for speaking at educational programs supported by ViroLogic, Visible Genetics, GlaxoSmithKline, Bristol-Myers Squibb, Roche Pharmaceuticals, and Agouron Pharmaceuticals; and directs a nonprofit academic laboratory at the Gladstone Institute of Virology and Immunology that has provided services for clinical research supported by grants to the University of California from Merck, GlaxoSmithKline, Bristol-Myers Squibb, Boehringer Ingelheim, Roche, Abbott, Agouron Pharmaceuticals, Gilead, Visible Genetics, and Chiron.

RG receives support for his HIV research from Agouron Pharmaceuticals, GlaxoSmithKline, and Bristol-Myers Squibb and serves as a consultant to GlaxoSmithKline; all relationships have been disclosed to the University of Pennsylvania, which deemed them not to constitute a conflict of interest.

Figures

Figure 1
Figure 1. Study Flow
Figure 2
Figure 2. Study Design (Phases I and II)
Figure 3
Figure 3. Lack of a Difference between Groups in Plasma HIV-1 RNA during Phase II
Top panel shows Kaplan-Meyer plot summarizing time to a viral load of more than 5,000 copies/ml in both arms. Second panel shows viral load (mean ± standard error) per arm during 27 wk of TI (median time of phase II). Bottom table shows number of patients at time points shown for viral load in the second panel; the decrease in viral load over time is due to the reinitiation of therapy in patients with higher viral loads.
Figure 4
Figure 4. T Cell Subsets and Recall Lymphoproliferative Response at the End of Phase I
End of phase I values for each arm are summarized (median and first and third quartiles) in the stacked figures showing from top to bottom: CD4 T cells/μl, CD4%, CD4−CD45RA+CD62L+% (naïve phenotype), CD8 T cells/μl, CD8%, and C. albicans lymphoproliferative response (shown as stimulation Index, SI). Unpaired p values for each variable are shown above corresponding bracket.
Figure 5
Figure 5. CD4 T Cells/μl and T Cell Recall Lymphoproliferative Response during Sequential TIs in Phase I
Shown are data from the repeated interruptions arm. Panels show the TI initiation visit and TI end visit of each sequential TI inclusive of the initiation visit for phase II (open-ended TI).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Yeni PG, Hammer SM, Hirsch MS, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA. 2004;292:251–265. - PubMed
    1. Gross R, Bilker WB, Friedman HM, Strom BL. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS. 2001;15:2109–2117. - PubMed
    1. Arya SC. Antiretroviral therapy in countries with low health expenditure. Lancet. 1998;351:1433–1434. - PubMed
    1. Stephenson J. AIDS researchers target poor adherence. JAMA. 1999;281:1069. - PubMed
    1. Bangsberg DR, Charlebois ED, Grant RM, Holodniy M, Deeks SG, et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS. 2003;17:1925–1932. - PubMed

Publication types

Substances